Amsacrine, Cytarabine and Thioguanine (AAT) versus Daunorubicin, Cytarabine, Thioguanine (DAT) in Adults with Untreated Acute Non-Lymphoblastic Leukemia (ANLL)

Autor:	G Michlmayr, R Keilhauer, J Düllmann, H Gerhartz, H Illinger, H König, D Moldrzyk, Werner Linkesch
Rok vydání:	1989
Předmět:	Cancer Research medicine.medical_specialty Myeloid business.industry Daunorubicin Hematology medicine.disease Gastroenterology Regimen Leukemia medicine.anatomical_structure Oncology Internal medicine Toxicity medicine Cytarabine business Amsacrine INDUCTION TREATMENT medicine.drug
Zdroj:	Oncology Research and Treatment. 12:8-10
ISSN:	2296-5262 2296-5270
Popis:	69 patients (median age 53 years, 19-79 years old) with untreated acute non-lymphoblastic leukemia (ANLL) were randomized to receive either a regimen of amsacrine, cytarabine, thioguanine (AAT) or daunorubicin, cytarabine, thioguanine (DAT). AAT consisted of amsacrine 200 mg/m2/day x 5, thioguanine 100 mg/m2/12 h p.o. x 10; DAT was daunorubicin 50 mg/m2/day x 3, cytarabine 200 mg/m2/day x 5, thioguanine 100 mg/m2/12 h p.o. x 10. After one or two induction courses the patients subsequently received 2 consolidation courses. 17 patients were not assessable for response to therapy due to exitus during induction treatment. Complete remission could be obtained in 14/24 (58%) of DAT patients respectively. Patients less than 60 years of age achieved CR in 63% (AAT) vs 65% (DAT), whereas patients greater than or equal to 60 years obtained a CR in 50% (AAT) vs 13% (DAT). Toxicity appears not to be increased significantly with amsacrine. These data indicate that amsacrine could replace daunorubicin in remission induction regimens of ANLL containing cytosin arabinoside and thioguanine without decreasing the response rate.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a5683d851ad6c383aeaa480920ba4f4a https://doi.org/10.1159/000216587 Zobrazit plný text záznamu